KYNB

Kyntra BioA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-03

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

25%

Probability

Target price

$10.50

+54.2% vs current

Most likely

Base case

45%

Probability

Target price

$6.50

-4.6% vs current

B-

Bear case

30%

Probability

Target price

$4.00

-41.3% vs current

AI sentiment snapshot

Latest data as of 2026-05-14

AI commentary

This T+3 earnings follow-up modestly improves operating visibility but not enough to change the monitoring posture. The company source confirmed intact pipeline milestones and liquidity support, yet checked sources did not surface clear post-print analyst target/rating revisions, and the stock-history check showed shares around $6.80 on May 11 and $6.90 on May 12 versus the $7.00 anchor on May 13, implying muted-to-negative initial reaction rather than a clean rerating. With low coverage, a live Nasdaq deadline, and still-negative deterministic returns, sentiment remains cautious.

RankAlpha Sentiment Codex - 2026-05-14

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-18eventNasdaq compliance plan deadline on May 18, 2026High impact

Kyntra said the Nasdaq notification has no immediate effect on listing, but it has until May 18, 2026 to submit a compliance plan and Nasdaq may grant up to a September 29, 2026 extension if the plan is accepted; that keeps listing status as the nearest binary overhang after earnings [#10-Q-2026-05-12].

2026-10-15catalystRoxadustat Phase 3 start decision in 2H 2026High impact

Management said the pivotal Phase 3 protocol for roxadustat in lower-risk MDS is being finalized following FDA feedback and that trial initiation is anticipated in the second half of 2026, but execution still depends on protocol completion, funding priorities, and potentially strategic partnering [#8-K-2026-05-11].

2026-11-15catalystFG-3246 Phase 2 interim analysis remains targeted for 4Q 2026High impact

The Q1 update kept the core oncology milestone intact: management said the Phase 2 FG-3246 monotherapy study in mCRPC is actively enrolling and remains on track for interim results in the fourth quarter of 2026, with ASCO GU combination data supporting trial design elements [#8-K-2026-05-11] [#10-Q-2026-05-12].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-14 • Updated nightlySource: Internal modelMethodology